225 related articles for article (PubMed ID: 36769597)
1. The Performance of GALAD Score for Diagnosing Hepatocellular Carcinoma in Patients with Chronic Liver Diseases: A Systematic Review and Meta-Analysis.
Guan MC; Zhang SY; Ding Q; Li N; Fu TT; Zhang GX; He QQ; Shen F; Yang T; Zhu H
J Clin Med; 2023 Jan; 12(3):. PubMed ID: 36769597
[TBL] [Abstract][Full Text] [Related]
2. Meta-analysis of the GALAD model for diagnosing primary hepatocellular carcinoma.
Lu JL; Yuan XY; Zhang JS; Li Y
Technol Health Care; 2024 May; ():. PubMed ID: 38759033
[TBL] [Abstract][Full Text] [Related]
3. GALAD Score Detects Early Hepatocellular Carcinoma in an International Cohort of Patients With Nonalcoholic Steatohepatitis.
Best J; Bechmann LP; Sowa JP; Sydor S; Dechêne A; Pflanz K; Bedreli S; Schotten C; Geier A; Berg T; Fischer J; Vogel A; Bantel H; Weinmann A; Schattenberg JM; Huber Y; Wege H; von Felden J; Schulze K; Bettinger D; Thimme R; Sinner F; Schütte K; Weiss KH; Toyoda H; Yasuda S; Kumada T; Berhane S; Wichert M; Heider D; Gerken G; Johnson P; Canbay A
Clin Gastroenterol Hepatol; 2020 Mar; 18(3):728-735.e4. PubMed ID: 31712073
[TBL] [Abstract][Full Text] [Related]
4. Comparison between models for detecting hepatocellular carcinoma in patients with chronic liver diseases of various etiologies: ASAP score versus GALAD score.
Sun LY; Wang NY; Diao YK; Yan CL; Fan ZP; Wei LH; Li HJ; Guan MC; Wang MD; Pawlik TM; Lau WY; Shen F; Lv GY; Yang T
Hepatobiliary Pancreat Dis Int; 2023 Dec; ():. PubMed ID: 38199909
[TBL] [Abstract][Full Text] [Related]
5. GALAD score and a proposal for GALADUS model for detecting hepatocellular carcinoma in Vietnamese patients with chronic liver disease.
Phuong PC; Khoa MT; Loi NT; Quynh VTT; Luan ND; Mai NTH; Dung NV; Hung NQ; Lieu DQ; Nam LV; Tra DT; Thai PV; Duc NM
Eur Rev Med Pharmacol Sci; 2024 Feb; 28(3):1111-1122. PubMed ID: 38375717
[TBL] [Abstract][Full Text] [Related]
6. GALAD Score Detects Early-Stage Hepatocellular Carcinoma in a European Cohort of Chronic Hepatitis B and C Patients.
Schotten C; Ostertag B; Sowa JP; Manka P; Bechmann LP; Hilgard G; Marquardt C; Wichert M; Toyoda H; Lange CM; Canbay A; Johnson P; Wedemeyer H; Best J
Pharmaceuticals (Basel); 2021 Jul; 14(8):. PubMed ID: 34451832
[TBL] [Abstract][Full Text] [Related]
7. GALAD Score for Hepatocellular Carcinoma Detection in Comparison with Liver Ultrasound and Proposal of GALADUS Score.
Yang JD; Addissie BD; Mara KC; Harmsen WS; Dai J; Zhang N; Wongjarupong N; Ali HM; Ali HA; Hassan FA; Lavu S; Cvinar JL; Giama NH; Moser CD; Miyabe K; Allotey LK; Algeciras-Schimnich A; Theobald JP; Ward MM; Nguyen MH; Befeler AS; Reddy KR; Schwartz M; Harnois DM; Yamada H; Srivastava S; Rinaudo JA; Gores GJ; Feng Z; Marrero JA; Roberts LR
Cancer Epidemiol Biomarkers Prev; 2019 Mar; 28(3):531-538. PubMed ID: 30464023
[TBL] [Abstract][Full Text] [Related]
8. Performance of GALAD score and serum biomarkers for detecting NAFLD-related HCC: a systematic review and network meta-analysis.
Li H; Liu H; Yan LJ; Ding ZN; Zhang X; Pan GQ; Han CL; Tian BW; Tan SY; Dong ZR; Wang DX; Yan YC; Li T
Expert Rev Gastroenterol Hepatol; 2023; 17(11):1159-1167. PubMed ID: 37929312
[TBL] [Abstract][Full Text] [Related]
9. ASAP Score
Liu SY; Li C; Sun LY; Guan MC; Gu LH; Yin DX; Yao LQ; Liang L; Wang MD; Xing H; Zhu H; Pawlik TM; Lau WY; Shen F; Tong XM; Yang T
Front Oncol; 2022; 12():1018396. PubMed ID: 36263214
[TBL] [Abstract][Full Text] [Related]
10. Validation of the GALAD model for early diagnosis and monitoring of hepatocellular carcinoma in Chinese multicenter study.
Huang C; Fang M; Xiao X; Wang H; Gao Z; Ji J; Liu L; Gu E; Li Y; Wang M; Gao C
Liver Int; 2022 Jan; 42(1):210-223. PubMed ID: 34679250
[TBL] [Abstract][Full Text] [Related]
11. Validation of the GALAD model and establishment of a new model for HCC detection in Chinese patients.
Li L; Lu F; Chen P; Song H; Xu W; Guo J; Wang J; Zhou J; Kang X; Jin C; Cai Y; Feng Z; Gao H
Front Oncol; 2022; 12():1037742. PubMed ID: 36620588
[TBL] [Abstract][Full Text] [Related]
12. Surveillance and treatment of primary hepatocellular carcinoma (aka. STOP HCC): protocol for a prospective cohort study of high-risk patients for HCC using GALAD-score.
Truong TN; Pham TND; Hoang LB; Nguyen VT; Dao HV; Dao DVB; Alessy S; Pham HB; Pham TTT; Nguyen LDD; Nguyen K; Abaalkhail F; Manal M; Mawardi M; AlZahrani M; Alswat K; Alghamdi H; Sanai FM; Siddiqui MA; Nguyen NH; Vaidya D; Phan HT; Johnson PJ; Alqahtani SA; Dao DY
BMC Cancer; 2023 Sep; 23(1):875. PubMed ID: 37723439
[TBL] [Abstract][Full Text] [Related]
13. The GALAD scoring algorithm based on AFP, AFP-L3, and DCP significantly improves detection of BCLC early stage hepatocellular carcinoma.
Best J; Bilgi H; Heider D; Schotten C; Manka P; Bedreli S; Gorray M; Ertle J; van Grunsven LA; Dechêne A
Z Gastroenterol; 2016 Dec; 54(12):1296-1305. PubMed ID: 27936479
[No Abstract] [Full Text] [Related]
14. Role of the GALAD and BALAD-2 Serologic Models in Diagnosis of Hepatocellular Carcinoma and Prediction of Survival in Patients.
Berhane S; Toyoda H; Tada T; Kumada T; Kagebayashi C; Satomura S; Schweitzer N; Vogel A; Manns MP; Benckert J; Berg T; Ebker M; Best J; Dechêne A; Gerken G; Schlaak JF; Weinmann A; Wörns MA; Galle P; Yeo W; Mo F; Chan SL; Reeves H; Cox T; Johnson P
Clin Gastroenterol Hepatol; 2016 Jun; 14(6):875-886.e6. PubMed ID: 26775025
[TBL] [Abstract][Full Text] [Related]
15. A multi-analyte cell-free DNA-based blood test for early detection of hepatocellular carcinoma.
Lin N; Lin Y; Xu J; Liu D; Li D; Meng H; Gallant MA; Kubota N; Roy D; Li JS; Gorospe EC; Sherman M; Gish RG; Abou-Alfa GK; Nguyen MH; Taggart DJ; Van Etten RA; Hoshida Y; Li W
Hepatol Commun; 2022 Jul; 6(7):1753-1763. PubMed ID: 35244350
[TBL] [Abstract][Full Text] [Related]
16. Validation of the GALAD Model and Establishment of GAAP Model for Diagnosis of Hepatocellular Carcinoma in Chinese Patients.
Liu M; Wu R; Liu X; Xu H; Chi X; Wang X; Zhan M; Wang B; Peng F; Gao X; Shi Y; Wen X; Ji Y; Jin Q; Niu J
J Hepatocell Carcinoma; 2020; 7():219-232. PubMed ID: 33123501
[TBL] [Abstract][Full Text] [Related]
17. Galad Score as a Prognostic Marker for Patients with Hepatocellular Carcinoma.
Cagnin S; Donghia R; Martini A; Pesole PL; Coletta S; Shahini E; Boninsegna G; Biasiolo A; Pontisso P; Giannelli G
Int J Mol Sci; 2023 Nov; 24(22):. PubMed ID: 38003675
[TBL] [Abstract][Full Text] [Related]
18. Abdominal ultrasound and alpha-foetoprotein for the diagnosis of hepatocellular carcinoma in adults with chronic liver disease.
Colli A; Nadarevic T; Miletic D; Giljaca V; Fraquelli M; Štimac D; Casazza G
Cochrane Database Syst Rev; 2021 Apr; 4(4):CD013346. PubMed ID: 33855699
[TBL] [Abstract][Full Text] [Related]
19. The APAC Score: A Novel and Highly Performant Serological Tool for Early Diagnosis of Hepatocellular Carcinoma in Patients with Liver Cirrhosis.
Lambrecht J; Porsch-Özçürümez M; Best J; Jost-Brinkmann F; Roderburg C; Demir M; Tacke F; Mohr R
J Clin Med; 2021 Jul; 10(15):. PubMed ID: 34362181
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of GALAD Score in Diagnosis and Follow-up of Hepatocellular Carcinoma after Local Ablative Therapy.
Eletreby R; Elsharkawy M; Taha AA; Hassany M; Abdelazeem A; El-Kassas M; Soliman A
J Clin Transl Hepatol; 2023 Apr; 11(2):334-340. PubMed ID: 36643039
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
